Browsing Tag
MIQNAF
3 posts
Wockhardt delivers strong FY25 EBITDA, but net loss persists amid US restructuring drag
Wockhardt posts a 67% EBITDA jump in FY25, but Q4 PAT remains negative. Find out how novel antibiotics like Zaynich and Miqnaf are shaping investor sentiment.
May 29, 2025
Wockhardt secures approval for Miqnaf: A breakthrough in pneumonia treatment
In a landmark decision addressing the global challenge of antibiotic resistance, the Indian drug regulator, Central Drugs Standard…
January 3, 2025
Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25,…
November 13, 2024